{"analyses":[{"ciLowerLimit":"0.93","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.59","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1498","paramType":"Hazard Ratio (HR)","paramValue":"1.21","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.1","upperLimit":"11.6","value":"9.0"},{"groupId":"OG001","lowerLimit":"6.1","upperLimit":"8.0","value":"6.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"The FACT-L measures health related QOL and composes of five domains: the four domains (physical well being, emotional well being, social well being, functional well being) from the FACT-G and the LCS. The FACT-L total score ranges from 0 to 136, higher scores represent better QOL. Time to deterioration of QoL or symptom progression is defined as time from randomization until either a clinically meaningful decline from baseline in Total FACT-L or, death on study, whichever occurs first. The clinically meaningful decline that was used to determine deterioration in QoL was ≥6-point decline from baseline. Participants without deterioration in QoL at the time of analysis were censored at the time of the last FACT-L assessment. Kaplan-Meier estimate was used to determine time to event.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received either pemetrexed 500 mg/m\\^2 every 21 days until disease progression, unacceptable toxicity or death or docetaxel 75 mg/m\\^2 every 3 weeks until disease progression, unacceptable toxicity or death. Choice of comparator was left to the discretion of the investigator in countries where both treatments are registered to use and are commercially available for second line use (otherwise, docetaxel was administered), assigning the participant to either comparator depending upon the medical needs of the participant. Participants were required to receive concomitant treatment therapy as indicated in the product label.","id":"OG000","title":"Comparator"},{"description":"Participants received erlotinib, 150 mg, administered orally as a tablet, once daily until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Erlotinib"}],"paramType":"MEDIAN","populationDescription":"FAS population; Only participants with both a baseline FACT-L assessment and a subsequent FACT-L assessment were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 3 and 6, Every 3 Weeks until Week 48 and Every 12 Weeks until Disease Progression or unacceptable toxicity up to 52 months","title":"Time to Deterioration in Quality of Life Using FACT-L","type":"SECONDARY","unitOfMeasure":"weeks"}